Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5008312 | 0.98 | DDR1 (0.39) | DDR1GAADGAT1POLBPARP1 | |
| SCHEMBL20577192 | 0.85 | POLB (0.34) | POLBHTTKDM4EALDH1A1 | |
| SCHEMBL597035 | 0.84 | DDR1 (0.41) | DDR1GAADGAT1NTRK1PRKCB | |
| Hydrochloric Acid SCHEMBL3822769 | 0.83 | POLB (0.33) | POLBHTT | |
| Hydrochloric Acid SCHEMBL3820275 | 0.83 | POLB (0.33) | POLBHTT | |
| SCHEMBL8616898 | 0.82 | DDR1 (0.40) | DDR1GAADGAT1NTRK1PRKCB | |
| SCHEMBL3826604 | 0.80 | LMNA (0.36) | DDR1POLBHTTKMT2AKDM4E | |
| SCHEMBL5008313 | 0.80 | MEN1 (0.37) | GAAPOLBHTTKMT2AKDM4E | |
| SCHEMBL3828653 | 0.78 | ELANE (0.43) | POLBHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL3828999 | 0.76 | NPSR1 (0.31) | DDR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202815-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202815-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | DDR1 1505/4885GAA 3378/4885DGAT1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.